CoChat

Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase

Open access

Published version of a preprint

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Abstract

Metabolic control is mediated by the dynamic assemblies and function of multiple redox enzymes. A key element in these assemblies, the P450 oxidoreductase (POR), donates electrons and selectively activates numerous (>50 in humans and >300 in plants) cytochromes P450 (CYPs) controlling metabolism of drugs, steroids and xenobiotics in humans and natural product biosynthesis in plants. The mechanisms underlying POR-mediated CYP metabolism remain poorly understood and to date no ligand binding has been described to regulate the specificity of POR. Here, using a combination of computational modeling and functional assays, we identify ligands that dock on POR and bias its specificity towards CYP redox partners, across mammal and plant kingdom. Single molecule FRET studies reveal ligand binding to alter POR conformational sampling, which results in biased activation of metabolic cascades in whole cell assays. We propose the model of biased metabolism, a mechanism akin to biased signaling of GPCRs, where ligand binding on POR stabilizes different conformational states that are linked to distinct metabolic outcomes. Biased metabolism may allow designing pathway-specific therapeutics or personalized food suppressing undesired, disease-related, metabolic pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-22562-w

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Small molecules dock on human POR and regulate electron transfer in vitro. A POR is the omnipotent electron donor to all CYPs in the ER membrane, activating metabolic cascades in both human and plants by transferring electrons to redox partners. Targeting POR with small-molecule ligands may bias metabolic outcomes and regulate basic metabolism in humans or tune the formation of natural products in plants. B Molecular structures of small-molecule ligands and their respective binding. Ligands (green) were docked on human POR with cofactors (yellow) in a compact conformation (PDB 3QE2) in Sites Ia and Ib determined from SiteMap analysis (see Supplementary Fig. 3A and Supplementary Table 1). Insets display the predicted binding conformations of cyclophosphamide (a + d), dhurrin (b + e), and rifampicin (c). See Supplementary Figs. 3–5 for higher magnification and detailed interactions and Supplementary Table 2 for binding energies. C In vitro activity of human POR proteoliposomes measured by the commonly used Cytc assay29. D Ligands bias human POR capacity to reduce Cytc in proteoliposomes at 100 μM, acting either as agonist (cyclophosphamide) or inverse agonizts (dhurrin and rifampicin). The bar plot represents the mean ± SD of independent replicates (n = 2–3; see Supplementary Table 3 for exact value of n for each experimental condition). Overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods and Supplementary Table 3 for details). Source data are provided as a Source Data file.
Fig. 1 Small molecules dock on human POR and regulate electron transfer in vitro. A POR is the omnipotent electron donor to all CYPs in the ER membrane, activating metabolic cascades in both human and plants by transferring electrons to redox partners. Targeting POR with small-molecule ligands may bias metabolic outcomes and regulate basic metabolism in humans or tune the formation of natural products in plants. B Molecular structures of small-molecule ligands and their respective binding. Ligands (green) were docked on human POR with cofactors (yellow) in a compact conformation (PDB 3QE2) in Sites Ia and Ib determined from SiteMap analysis (see Supplementary Fig. 3A and Supplementary Table 1). Insets display the predicted binding conformations of cyclophosphamide (a + d), dhurrin (b + e), and rifampicin (c). See Supplementary Figs. 3–5 for higher magnification and detailed interactions and Supplementary Table 2 for binding energies. C In vitro activity of human POR proteoliposomes measured by the commonly used Cytc assay29. D Ligands bias human POR capacity to reduce Cytc in proteoliposomes at 100 μM, acting either as agonist (cyclophosphamide) or inverse agonizts (dhurrin and rifampicin). The bar plot represents the mean ± SD of independent replicates (n = 2–3; see Supplementary Table 3 for exact value of n for each experimental condition). Overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods and Supplementary Table 3 for details). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Small-molecule ligands bias specificity of human POR to reduce diverse electron acceptors. A Human POR proteoliposome activity to reduce diverse electron acceptors was assessed using 100 μM NADPH and 10 μM RS (left), 500 μM MTT (middle) or 40 μM Cytc (right) by monitoring changes in absorbance (550 nm for Cytc, 610 nm for MTT) or fluorescence (582 nm for RS). Note the increased noise due to less sensitive UV–VIS readout for Cytc. All activity traces depict the mean ± SD of at least three independent measurements. POR activity was extracted by fitting the linear region of the traces. B Ligands affect the electron donating capacity of human POR differentially dependent on the electron acceptor indicating biased specificity. Rifampicin reduces POR activity towards Cytc, has a small effect on MTT reduction and enhances POR activity to reduce the electron acceptor resazurin by 3-fold. Cyclophosphamide results in minute increased activity towards Cytc, while dhurrin reduces activity towards Cytc. The bar plot represents the mean ± SD of independent replicates normalized to DMSO controls with propagated error (n = 2–6; see Supplementary Methods and Supplementary Table 3 for exact value of n for each experimental condition). Note, overlapping data points appear shaded. Data for Cytc from Fig. 1 are included for comparison. All data are corrected for potential ligand photophysical effect (see Supplementary Fig. 7). Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source data are provided as a Source Data file.
Fig. 2 Small-molecule ligands bias specificity of human POR to reduce diverse electron acceptors. A Human POR proteoliposome activity to reduce diverse electron acceptors was assessed using 100 μM NADPH and 10 μM RS (left), 500 μM MTT (middle) or 40 μM Cytc (right) by monitoring changes in absorbance (550 nm for Cytc, 610 nm for MTT) or fluorescence (582 nm for RS). Note the increased noise due to less sensitive UV–VIS readout for Cytc. All activity traces depict the mean ± SD of at least three independent measurements. POR activity was extracted by fitting the linear region of the traces. B Ligands affect the electron donating capacity of human POR differentially dependent on the electron acceptor indicating biased specificity. Rifampicin reduces POR activity towards Cytc, has a small effect on MTT reduction and enhances POR activity to reduce the electron acceptor resazurin by 3-fold. Cyclophosphamide results in minute increased activity towards Cytc, while dhurrin reduces activity towards Cytc. The bar plot represents the mean ± SD of independent replicates normalized to DMSO controls with propagated error (n = 2–6; see Supplementary Methods and Supplementary Table 3 for exact value of n for each experimental condition). Note, overlapping data points appear shaded. Data for Cytc from Fig. 1 are included for comparison. All data are corrected for potential ligand photophysical effect (see Supplementary Fig. 7). Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Small-molecule ligands bias specificity of plant POR (SbPOR2b) to reduce diverse electron acceptors. A Effects of small-molecule ligands on SbPOR2b activity in proteoliposomes using Cytc and RS as electron acceptors. B Dose-response curves of rifampicin, cyclophosphamide and dhurrin in the Cytc and RS assays, respectively. Rifampicin acts as an agonist towards Cytc enhancing its reduction rate and inverse agonist towards RS reducing the reduction rate. Cyclophosphamide displays the reverse effect acting as an inverse agonist towards Cytc reduction and agonist towards RS reduction. Dhurrin acts as an agonist towards both Cytc and RS reduction at low micromolar concentrations. The fact that ligands display differential effects on SbPOR2b activity to reduce the two electron acceptors indicates biased specificity of POR. IC50 values are extracted from the Hill equation. A, B The bar plots and dose-response curves represent the mean ± SD of independent replicates normalized to controls with propagated error (n = 3–12; see Supplementary Fig. 9 for raw data and Supplementary Table 3 for exact value of n for each experimental condition). All data are corrected for potential ligand photophysical effect (see Supplementary Fig. 7). Note, overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source data are provided as a Source Data file.
Fig. 3 Small-molecule ligands bias specificity of plant POR (SbPOR2b) to reduce diverse electron acceptors. A Effects of small-molecule ligands on SbPOR2b activity in proteoliposomes using Cytc and RS as electron acceptors. B Dose-response curves of rifampicin, cyclophosphamide and dhurrin in the Cytc and RS assays, respectively. Rifampicin acts as an agonist towards Cytc enhancing its reduction rate and inverse agonist towards RS reducing the reduction rate. Cyclophosphamide displays the reverse effect acting as an inverse agonist towards Cytc reduction and agonist towards RS reduction. Dhurrin acts as an agonist towards both Cytc and RS reduction at low micromolar concentrations. The fact that ligands display differential effects on SbPOR2b activity to reduce the two electron acceptors indicates biased specificity of POR. IC50 values are extracted from the Hill equation. A, B The bar plots and dose-response curves represent the mean ± SD of independent replicates normalized to controls with propagated error (n = 3–12; see Supplementary Fig. 9 for raw data and Supplementary Table 3 for exact value of n for each experimental condition). All data are corrected for potential ligand photophysical effect (see Supplementary Fig. 7). Note, overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Material for details). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Direct observation of POR biased conformational sampling by small-molecule ligands using smFRET. A Illustration of smFRET assay using TIRF microscopy. Top; SbPOR2b is site-specifically labeled with Cy3/Cy5 fluorophores, reconstituted in lipid nanodiscs and tethered on a passivated microscope surface. Bottom; representative smFRET traces displaying FRET states and dynamic transitions between them (see Supplementary Fig. 12 for more examples). Top row: Donor (green) and acceptor (red) intensities over time (s). Middle row: acceptor only intensity (red), bottom row: EFRET values (orange) calculated with calibration factors, and idealized FRET value determined from HMM fitting (blue). B Distribution of FRET efficiencies in the absence and presence of ligands. Distributions are optimally fit with 5 states for all conditions as determined from BIC (see Supplementary Methods and Supplementary Fig. 13) with average distances ranging from ~40 to ~80 Å. Rifampicin, cyclophosphamide and dhurrin alter the occupancies of each of the five FRET states indicating biased conformational sampling. Colored bars on top of histograms represent occupancies of each state. N denotes of the number of single molecules at each experimental condition. C FRET efficiencies and converted inter-dye distances obtained from five-state gaussian mixture models. Each FRET state may reflect an equilibrium between multiple conformations. D Homology modeling of SbPOR2b from crystal structures of POR isoforms in a compact, intermediate conformation and a human-yeast chimera in a fully extended conformation (PDBs: 3QE2, 3ES9 and 3FJO respectively) with Monte Carlo simulated inter-dye distances (bold) and Cα-Cα distances (brackets). Source data are provided as a Source Data file.
Fig. 4 Direct observation of POR biased conformational sampling by small-molecule ligands using smFRET. A Illustration of smFRET assay using TIRF microscopy. Top; SbPOR2b is site-specifically labeled with Cy3/Cy5 fluorophores, reconstituted in lipid nanodiscs and tethered on a passivated microscope surface. Bottom; representative smFRET traces displaying FRET states and dynamic transitions between them (see Supplementary Fig. 12 for more examples). Top row: Donor (green) and acceptor (red) intensities over time (s). Middle row: acceptor only intensity (red), bottom row: EFRET values (orange) calculated with calibration factors, and idealized FRET value determined from HMM fitting (blue). B Distribution of FRET efficiencies in the absence and presence of ligands. Distributions are optimally fit with 5 states for all conditions as determined from BIC (see Supplementary Methods and Supplementary Fig. 13) with average distances ranging from ~40 to ~80 Å. Rifampicin, cyclophosphamide and dhurrin alter the occupancies of each of the five FRET states indicating biased conformational sampling. Colored bars on top of histograms represent occupancies of each state. N denotes of the number of single molecules at each experimental condition. C FRET efficiencies and converted inter-dye distances obtained from five-state gaussian mixture models. Each FRET state may reflect an equilibrium between multiple conformations. D Homology modeling of SbPOR2b from crystal structures of POR isoforms in a compact, intermediate conformation and a human-yeast chimera in a fully extended conformation (PDBs: 3QE2, 3ES9 and 3FJO respectively) with Monte Carlo simulated inter-dye distances (bold) and Cα-Cα distances (brackets). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Biased metabolism: small-molecule ligands bias steroidogenic CYP-activities in human cells and microsomes. A A human adrenocortical cell line (NCI-H295R) was used to assess the effect of small-molecule ligands on steroidogenic CYP17A1 and CYP21A2 hydroxylase activity, and CYP17A1 lyase activity, using radiolabeled substrates (see Supplementary Methods and Supplementary Table 4). Cell viability was assessed based on MTT reduction. Rifampicin shows a small inhibiting effect towards CYP21A2. The cells display increased MTT reduction indicating increased reductase activity. No significant effects on CYP17A1 activities are observed. Cyclophosphamide causes a significance increase in CYP17A1 lyase and less significant towards 17-OHase and 21A2 activities, while MTT reduction decreases slightly. Dhurrin causes inhibition of both CYP17A1 and CYP21A2 activities. B Abiraterone was used as a control inhibitor of CYP17A1 and CYP21A2 in H295R cells. C The effect of ligands on CYP19A1 activity was assessed on microsomes from a human choriocarcinoma cell line (JEG3). Rifampicin shows a concentration dependent inhibitory effect on CYP19A1 activity (32 ± 11% of control). Cyclophosphamide and dhurrin display no significant effect. A, C Error bars represent mean ± SD of 3–4 biological replicates normalized to DMSO controls with propagated error. See Supplementary Fig. 14 for raw data and Supplementary Table 4 for exact value of n for each experimental condition. Note, overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods for details). Source data are provided as a Source Data file.
Fig. 5 Biased metabolism: small-molecule ligands bias steroidogenic CYP-activities in human cells and microsomes. A A human adrenocortical cell line (NCI-H295R) was used to assess the effect of small-molecule ligands on steroidogenic CYP17A1 and CYP21A2 hydroxylase activity, and CYP17A1 lyase activity, using radiolabeled substrates (see Supplementary Methods and Supplementary Table 4). Cell viability was assessed based on MTT reduction. Rifampicin shows a small inhibiting effect towards CYP21A2. The cells display increased MTT reduction indicating increased reductase activity. No significant effects on CYP17A1 activities are observed. Cyclophosphamide causes a significance increase in CYP17A1 lyase and less significant towards 17-OHase and 21A2 activities, while MTT reduction decreases slightly. Dhurrin causes inhibition of both CYP17A1 and CYP21A2 activities. B Abiraterone was used as a control inhibitor of CYP17A1 and CYP21A2 in H295R cells. C The effect of ligands on CYP19A1 activity was assessed on microsomes from a human choriocarcinoma cell line (JEG3). Rifampicin shows a concentration dependent inhibitory effect on CYP19A1 activity (32 ± 11% of control). Cyclophosphamide and dhurrin display no significant effect. A, C Error bars represent mean ± SD of 3–4 biological replicates normalized to DMSO controls with propagated error. See Supplementary Fig. 14 for raw data and Supplementary Table 4 for exact value of n for each experimental condition. Note, overlapping data points appear shaded. Level of significance is determined by one-way ANOVA and Tukey’s HSD test correcting for multiple comparisons (*p < 0.05; **p < 0.01; ***p < 0.005; see Supplementary Methods for details). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Cartoon representation of the concept of biased metabolism a mechanism akin to biased signaling of GPCRs but for metabolic hubs. Ligand binding on POR appears to remodel its energy landscape, alter its conformational sampling consequently biasing downstream CYP activation by inhibiting the activation of a subset of CYPs and/or enhancing the activation of others. Targeting POR may act as a hitherto unknown paradigm for metabolic control in human and plants. Complete understanding of biased metabolism may offer the in silico design of pathways specific pharmaceutics or personalized food suppressing undesired, disease related, metabolic pathways.
Fig. 6 Cartoon representation of the concept of biased metabolism a mechanism akin to biased signaling of GPCRs but for metabolic hubs. Ligand binding on POR appears to remodel its energy landscape, alter its conformational sampling consequently biasing downstream CYP activation by inhibiting the activation of a subset of CYPs and/or enhancing the activation of others. Targeting POR may act as a hitherto unknown paradigm for metabolic control in human and plants. Complete understanding of biased metabolism may offer the in silico design of pathways specific pharmaceutics or personalized food suppressing undesired, disease related, metabolic pathways.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 73

Metadata

Authors
Jensen, S. B., Thodberg, S., Parween, S., Moses, M. E., Hansen, C. C., Thomsen, J., Sletfjerding, M. B., Knudsen, C., Del Giudice, R., Lund, P. M., Castaño, P. R., Bustamante, Y. G., Velazquez, M. N. R., Jørgensen, F. S., Pandey, A. V., Laursen, T., Møller, B. L., & Hatzakis, N. S.
Affiliations
  • University of Copenhagen (DK)
  • University of Bern (CH)
Corresponding author
Hatzakis, Nikos S.
Venue
Nature Communications
Published
2021-04-15
Volume
12
Issue
1
Pages
2260-2260
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3153199601
Cited by
64
References
74
Citations by year
2026: 4 · 2025: 17 · 2024: 14 · 2023: 7 · 2022: 16 · 2021: 6
FWCI
3.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Open Access CRIS of the University of Bern
Funders
  • Novartis Stiftung für Medizinisch-Biologische Forschung (18A053)
  • Swiss National Science foundation
  • Det Frie Forskningsråd (7026-00041B)
  • Novo Nordisk Fonden (NNF17OC0024886, NNF14CC0001)
  • Velux Fonden (10099, 18333)
  • Carlsbergfondet (CF16-0797)
Topics
  • Physical Sciences › Chemistry › Inorganic Chemistry › Metal-Catalyzed Oxygenation Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords
cytochrome P450 oxidoreductase, cytochrome P450, ligand binding, enzyme specificity, conformational sampling, single-molecule FRET, metabolic control, drug metabolism, xenobiotic metabolism, biased signaling
MeSH terms
Single Molecule Imaging, Aromatase, Cell Line, Cytochrome P-450 Enzyme System, Humans, Ligands, Liposomes, Protein Binding, Recombinant Proteins, Steroid 17-alpha-Hydroxylase, Steroid 21-Hydroxylase, Substrate Specificity, Protein Structure, Tertiary, Fluorescence Resonance Energy Transfer, Metabolic Networks and Pathways, Enzyme Assays, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase. https://app.cochat.ai/papers/10.1038/s41467-021-22562-w
The paper
Jensen, S. B., Thodberg, S., Parween, S., Moses, M. E., Hansen, C. C., Thomsen, J., Sletfjerding, M. B., Knudsen, C., Del Giudice, R., Lund, P. M., Castaño, P. R., Bustamante, Y. G., Velazquez, M. N. R., Jørgensen, F. S., Pandey, A. V., Laursen, T., Møller, B. L., & Hatzakis, N. S. (2021). Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductase. Nature Communications. https://doi.org/10.1038/s41467-021-22562-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.